2022
Antithrombotic Therapy After Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation
Freeman JV, Higgins AY, Wang Y, Du C, Friedman DJ, Daimee UA, Minges KE, Pereira L, Goldsweig AM, Price MJ, Reddy VY, Gibson D, Doshi SK, Varosy PD, Masoudi FA, Curtis JP. Antithrombotic Therapy After Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation. Journal Of The American College Of Cardiology 2022, 79: 1785-1798. PMID: 35512858, PMCID: PMC9097170, DOI: 10.1016/j.jacc.2022.02.047.Peer-Reviewed Original ResearchMeSH KeywordsAnticoagulantsAspirinAtrial AppendageAtrial FibrillationFibrinolytic AgentsFrailtyHumansStrokeTreatment OutcomeWarfarinConceptsLeft atrial appendage occlusionAdverse eventsPivotal trialsWatchman deviceTreatment protocolAntithrombotic strategiesAppendage occlusionLower riskFrailty regressionPercutaneous left atrial appendage occlusionNational Cardiovascular Data RegistryContemporary U.S. practiceDual antiplatelet therapyAtrial appendage occlusionConcomitant aspirinPostprocedure careAdjusted riskAntiplatelet therapyAntithrombotic medicationAntithrombotic therapyAtrial fibrillationAdverse outcomesTrial protocolAntithrombotic agentsMedication strategiesPatient-Level Analysis of Watchman Left Atrial Appendage Occlusion in Practice Versus Clinical Trials
Friedman DJ, Du C, Wang Y, Agarwal V, Varosy PD, Masoudi FA, Holmes DR, Reddy VY, Price MJ, Curtis JP, Freeman JV. Patient-Level Analysis of Watchman Left Atrial Appendage Occlusion in Practice Versus Clinical Trials. JACC Cardiovascular Interventions 2022, 15: 950-961. PMID: 35512918, PMCID: PMC9370831, DOI: 10.1016/j.jcin.2022.02.029.Peer-Reviewed Original ResearchConceptsRegistry patientsHemorrhagic stroke riskIschemic strokeWarfarin patientsTrial patientsStroke riskLAAO patientsClinical practiceMore pericardial effusionsPeriprocedural ischemic strokePropensity-matched analysisAtrial appendage occlusionCox proportional hazardsPatient-level dataFine-Gray modelMore comorbiditiesPROTECT AFNoncardiovascular deathPericardial effusionHemorrhagic strokeAppendage occlusionDevice implantationTrial criteriaClinical trialsSimilar risk
2021
Prognosis of Claims‐ Versus Trial‐Based Ischemic and Bleeding Events Beyond 1 Year After Coronary Stenting
Butala NM, Faridi KF, Secemsky EA, Song Y, Curtis J, Gibson CM, Kazi D, Shen C, Yeh RW. Prognosis of Claims‐ Versus Trial‐Based Ischemic and Bleeding Events Beyond 1 Year After Coronary Stenting. Journal Of The American Heart Association 2021, 10: e018744. PMID: 33682431, PMCID: PMC8174225, DOI: 10.1161/jaha.120.018744.Peer-Reviewed Original ResearchConceptsUnadjusted mortality ratesIschemic eventsDAPT studyMortality rateEnd pointCox proportional hazards modelPercutaneous coronary interventionProportional hazards modelCardiovascular clinical trialsTrial adjudicationBleeding eventsCathPCI RegistryCoronary interventionCoronary stentingSimilar prognosisPrognostic significanceClinical eventsClinical trialsMedicare claimsAdministrative claimsMortality riskHazards modelPatientsPrognosisDeath
2020
Duration of P2Y12 inhibitor Prescription After Percutaneous Coronary Intervention in Patients on Oral Anticoagulants (from NCDR CathPCI Registry)
Saad M, Tobolski J, Kolte D, Wang Y, Minges K, Hira RS, Curtis JP, Abbott JD. Duration of P2Y12 inhibitor Prescription After Percutaneous Coronary Intervention in Patients on Oral Anticoagulants (from NCDR CathPCI Registry). The American Journal Of Cardiology 2020, 133: 182-184. PMID: 32819682, DOI: 10.1016/j.amjcard.2020.07.029.Peer-Reviewed Original Research
2015
Hospital Variability in Use of Anticoagulant Strategies During Acute Myocardial Infarction Treated With an Early Invasive Strategy
Arnold SV, Li SX, Alexander KP, Spertus JA, Nallamothu BK, Curtis JP, Kosiborod M, Gupta A, Wang TY, Lin H, Dharmarajan K, Strait KM, Lowe TJ, Krumholz HM. Hospital Variability in Use of Anticoagulant Strategies During Acute Myocardial Infarction Treated With an Early Invasive Strategy. Journal Of The American Heart Association 2015, 4: e002009. PMID: 26077589, PMCID: PMC4599539, DOI: 10.1161/jaha.115.002009.Peer-Reviewed Original ResearchConceptsEarly invasive strategyAnticoagulant strategiesMyocardial infarctionBleeding rateInvasive strategyAcute myocardial infarction patientsOptimal anticoagulant strategyHalf of patientsPercutaneous coronary interventionAcute myocardial infarctionMyocardial infarction patientsHospital use patternsComparative effectiveness studiesRisk-standardized mortalityChoice of anticoagulantsMedian odds ratioCoronary interventionPatient factorsSystemic anticoagulationHospital variabilityInfarction patientsPrincipal diagnosisOdds ratioMultivariate regression modelPatterns of useFrequency and Effects of Excess Dosing of Anticoagulants in Patients ≤55 Years With Acute Myocardial Infarction Who Underwent Percutaneous Coronary Intervention (from the VIRGO Study)
Gupta A, Chui P, Zhou S, Spertus JA, Geda M, Lorenze N, Lee I, Onofrio G, Lichtman JH, Alexander KP, Krumholz HM, Curtis JP. Frequency and Effects of Excess Dosing of Anticoagulants in Patients ≤55 Years With Acute Myocardial Infarction Who Underwent Percutaneous Coronary Intervention (from the VIRGO Study). The American Journal Of Cardiology 2015, 116: 1-7. PMID: 25937348, PMCID: PMC4466069, DOI: 10.1016/j.amjcard.2015.03.032.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge DistributionAngioplasty, Balloon, CoronaryAnticoagulantsAntithrombinsBody Mass IndexCohort StudiesFemaleHemorrhageHeparinHirudinsHumansMaleMiddle AgedMyocardial InfarctionPeptide FragmentsPercutaneous Coronary InterventionPlatelet Glycoprotein GPIIb-IIIa ComplexPrevalenceRecombinant ProteinsRisk AssessmentRisk FactorsSex DistributionTreatment OutcomeUnited StatesConceptsPercutaneous coronary interventionGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsExcess dosingAcute myocardial infarctionCoronary interventionMultivariable analysisMyocardial infarctionUnderwent Percutaneous Coronary InterventionLower body weightOlder patientsYounger patientsUnfractionated heparinMedical recordsUnivariate analysisAnticoagulant agentsAnticoagulant drugsBody weightPatientsDosingYounger ageLogistic regressionYoung womenAnticoagulantsGender-based differences